⚠ A Regulator Can Change How Many Blades a Procedure NeedsHigh threat

Intuitive Surgical (ISRG) — threat to the moat

The FDA already raised the Ion catheter from five uses to eight, and Intuitive has now volunteered to do the same to EndoWrist.

The instrument use limit is presented, correctly, as a safety control. It is also the variable that sets consumable revenue per procedure, and Intuitive does not have the last word on it.

Permitted uses of the Ion catheter5 usesBefore April 20248 usesAfter FDA clearanceCleared by the FDA in April 2024 and certified in Europe in February 2025.
A 60% extension on one product, sought by Intuitive itself. Applied to the $6,018.9M instrument line, the same move is a very large number.

The precedent is in the filings. In April 2024 the company obtained FDA clearance to extend the number of uses of the Ion catheter from five to eight, and in February 2025 obtained European certification for the same change1. Intuitive sought that clearance itself, presumably because customers wanted it and because a lower cost per procedure widens adoption. But the direction of travel is what matters: once a device has demonstrated it can safely do eight procedures, the argument that it must be discarded after five is gone.

Da Vinci instruments are described in the same terms — "most are reusable for a defined number of procedures", with the chip enforcing the count2. Applied across the $6,018.9 million instruments and accessories line, a one-third extension of average instrument life would be a very large number, and it would arrive without any competitor doing anything.

Pressure in that direction is building from two sides. Hospitals under cost pressure want fewer disposables per case, and third-party reprocessors have long argued that single-use and limited-use designations on surgical devices are commercially rather than clinically motivated. Intuitive's defence is genuine: performance specification, validated cycles, and the fact that it, not a reprocessor, carries the regulatory liability.

Watch instruments and accessories revenue against procedure growth. In 2025 procedures grew 18% and this line grew 19%3, so the revenue per procedure was steady. A sustained gap — procedures growing faster than consumables — is what an extension of instrument life looks like in the accounts, and it would show up before anybody announced it.

References
  1. ReportedIn April 2024 the company obtained FDA clearance to extend the number of uses of the Ion catheter from five to eight, and in February 2025 obtained European certification for the same change.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
  2. ReportedDa Vinci instruments are described in the same terms — "most are reusable for a defined number of procedures", with the chip enforcing the count.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  3. ReportedIn 2025 procedures grew 18% and this line grew 19%, so the revenue per procedure was steady.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
Sources
Generated September 23, 2026